1. Moon JH, Kim KM, Oh TJ, Choi SH, Lim S, Park YJ, et al. The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2017;102:78-85.
[CROSSREF]
2. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
[CROSSREF] [PUBMED] [PMC]
3. Pötter E, Horn R, Scheumann GF, Dralle H, Costagliola S, Ludgate M, et al. Western blot analysis of thyrotropin receptor expression in human thyroid tumours and correlation with TSH-binding. Biochem Biophys Res Commun 1994;205:361-367.
[CROSSREF] [PUBMED]
4. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 2008;93:1167-1169.
[CROSSREF] [PDF]
5. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-744.
[CROSSREF] [PUBMED]
6. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-1242.
[CROSSREF]
7. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554-564.
[CROSSREF] [PUBMED]
8. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:2610-2615.
[CROSSREF] [PUBMED] [PDF]
9. Parker WA, Edafe O, Balasubramanian SP. Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature. Pragmat Obs Res 2017;8:57-67.
[CROSSREF] [PUBMED] [PMC]
10. Klein Hesselink EN, Klein Hesselink MS, de Bock GH, Gansevoort RT, Bakker SJ, Vredeveld EJ, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 2013;31:4046-4053.
[CROSSREF] [PUBMED]
11. Pajamaki N, Metso S, Hakala T, Ebeling T, Huhtala H, Ryodi E, et al. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2018;88:303-310.
[CROSSREF] [PUBMED]
12. Wang LY, Smith AW, Palmer FL, Tuttle RM, Mahrous A, Nixon IJ, et al. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid 2015;25:300-307.
[CROSSREF] [PUBMED] [PMC]
13. Tournis S, Antoniou JD, Liakou CG, Christodoulou J, Papakitsou E, Galanos A, et al. Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin Endocrinol (Oxf) 2015;82:197-204.
[CROSSREF] [PUBMED]
14. Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011;150:1250-1257.
[CROSSREF] [PUBMED]
15. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012. J Clin Endocrinol Metab 2015;100:3270-3279.
[CROSSREF] [PUBMED] [PMC]
16. Sugitani I, Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab 2010;95:4576-4583.
[CROSSREF] [PUBMED]
17. Park S, Kim WG, Han M, Jeon MJ, Kwon H, Kim M, et al. Thyrotropin suppressive therapy for low-risk small thyroid cancer: a propensity score-matched cohort study. Thyroid 2017;27:1164-1170.
[CROSSREF] [PUBMED]
18. Cox C, Bosley M, Southerland LB, Ahmadi S, Perkins J, Roman S, et al. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines? Surgery 2018;163:75-80.
[CROSSREF] [PUBMED]
19. Park S, Jeon MJ, Song E, Oh HS, Kim M, Kwon H, et al. Clinical features of early and late postoperative hypothyroidism after lobectomy. J Clin Endocrinol Metab 2017;102:1317-1324.
[CROSSREF] [PUBMED]
20. Ebina A, Sugitani I, Fujimoto Y, Yamada K. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients? Surgery 2014;156:1579-1588.
[CROSSREF] [PUBMED]
21. Park YM, Lee DY, Oh KH, Cho JG, Baek SK, Kwon SY, et al. Clinical implications of pathologic factors after thyroid lobectomy in patients with papillary thyroid carcinoma. Oral Oncol 2017;75:1-5.
[CROSSREF] [PUBMED]
22. Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8,676 patients at a single institution. Surgery 2017;161:485-492.
[CROSSREF] [PUBMED]
23. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 2014;38:68-79.
[CROSSREF] [PUBMED] [PDF]
24. Hwangbo Y, Kim JM, Park YJ, Lee EK, Lee YJ, Park DJ, et al. Long-term recurrence of small papillary thyroid cancer and its risk factors in a Korean multicenter study. J Clin Endocrinol Metab 2017;102:625-633.
[CROSSREF] [PUBMED] [PDF]
25. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428.
[CROSSREF] [PUBMED]